{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:42:59Z","timestamp":1778776979295,"version":"3.51.4"},"reference-count":100,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,3,4]]},"DOI":"10.1080\/13543784.2023.2184684","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T17:21:23Z","timestamp":1677864083000},"page":"229-243","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Investigational systemic drugs for moderate to severe plaque psoriasis: What\u2019s new?"],"prefix":"10.1080","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5238-2336","authenticated-orcid":false,"given":"Laura","family":"Calabrese","sequence":"first","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalma","family":"Malvaso","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flaminia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mannino","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-0463","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.023"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/ng.311"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00296-6"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01210"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.340"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.169"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/nri3834"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013068"},{"issue":"1","key":"cit0021","first-page":"122","volume":"19","author":"Calabrese L","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.259"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010179"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.004"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.20.06658-4"},{"issue":"2","key":"cit0028","first-page":"ii65","volume":"64","author":"Feldman SR","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.5070\/D30W66C5GG"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S294173"},{"key":"cit0031","unstructured":"FDA approval of Remicade (infliximab) for the treatment of psoriasis. Published November 2013 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0032","unstructured":"FDA approval of Humira (Adalimumab) for the treatment of psoriasis. Published December 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125057s417lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0033","unstructured":"FDA approval of Cimzia (certolizumab) for the treatment of psoriasis. Published April 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0034","unstructured":"FDA approval of Enbrel (etanercept) for the treatment of psoriasis. Published September 2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"cit0036","unstructured":"FDA approval of Cosentyx (secukinumab) for the treatment of psoriasis. Published May 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504s043lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0037","unstructured":"FDA approval of Taltz (ixekizumab) for the treatment of psoriasis. Published December 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125521s004lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0038","unstructured":"FDA approval of Siliq (brodalumab) for the treatment of psoriasis. Published 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf. Cited 2022 Nov 23"},{"key":"cit0039","unstructured":"EMA approval of Bimzelx (bimekizumab) for the treatment of psoriasis. Published August 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Cited 2022 Nov 23"},{"key":"cit0040","unstructured":"FDA approval of Stelara (ustekinumab) for the treatment of psoriasis. Published September 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf. Cited 2022 Nov 24"},{"key":"cit0041","unstructured":"FDA approval of Tremfya (guselkumab) for the treatment of psoriasis. Published July 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761061s007lbl.pdf. Cited 2022 Nov 24"},{"key":"cit0042","unstructured":"FDA approval of Ilumya (Tildrakizumab) for the treatment of psoriasis. Published March 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761067s000lbl.pdf. Cited 2022 Nov 24"},{"key":"cit0043","unstructured":"FDA approval of Skyrizi (Risankizumab) for the treatment of psoriasis. Published January 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761105s014lbl.pdf. Cited 2022 Nov 24"},{"key":"cit0044","unstructured":"FDA approval of Otezla (Apremilast) for the treatment of psoriasis. Published June 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205437s006lbl.pdf. Cited 2022 Nov 24"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1134319"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.536"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S297631"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.005"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.688"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100466"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792267"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04329.x"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2091"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152468"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17195"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.059"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1948833"},{"issue":"1","key":"cit0061","first-page":"93","volume":"183","author":"Haggerty HG","year":"2021","journal-title":"Toxicol Sci"},{"key":"cit0062","unstructured":"Vitae pharmaceuticals, 8-K - current report, published: 2016-Mar16. [cited 2021 Mar 15]. Available from: https:\/\/sec.report\/Document\/0001104659-16-105501\/"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00151.x"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999852"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.05.011"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1038\/302305a0"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.07.003"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4228"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.09.003"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.039"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000073"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020271"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11624"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.679704"},{"key":"cit0077","unstructured":"EMA approval of Skilarence (dimethyl fumarate) for the treatment of psoriasis. Published June 2017 Skilarence, INN-dimethyl fumarate (europa.eu). Cited 2022 Nov 24."},{"issue":"1","key":"cit0078","first-page":"53","volume":"15","author":"Mrowietz U","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02124.x"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14947"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1128"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42856"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad8953"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414189111"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602142"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12466250"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1186\/1476-9255-11-10"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2498"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1002\/iub.607"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.002"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20200351"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12049"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14302"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1838"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20880"},{"key":"cit0096","unstructured":"Evelo biosciences presents late-breaking oral abstract on data from phase 2 trial of EDP1815 in psoriasis at 2022 American Academy of Dermatology annual meeting. Evelo Biosciences. Press release. Published March 26, 2022. Available from: https:\/\/ir.evelobio.com\/news-releases\/news-release-details\/evelo-biosciences-presents-late-breaking-oral-abstract-data\/. Cited 2022 Dec 3."},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0832-y"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12654"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2184684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:24:14Z","timestamp":1680189854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2184684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,4]]}},"alternative-id":["10.1080\/13543784.2023.2184684"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2184684","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}